Precigen, Inc. - Common Stock (NQ:PGEN)

8.540 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Precigen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal ↗

June 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Aethlon Medical, Inc. (...

Via Benzinga

Precigen: Return On Capital Employed Insights ↗

June 09, 2021

Precigen (NASDAQ:PGEN) reported Q1 sales of $24.51 million. Earnings fell to a loss of $17.69 million, resulting in a 598.82% decrease from last quarter. In Q4, Precigen earned $3...

Via Benzinga

Exclusive: Precigen's CEO Breaks Down Biotech's Oncology Platforms, Technology, Differentiators ↗

April 06, 2021

Cancer treatment has evolved from the use of chemotherapeutic anti-tumor drugs to targeted therapies to monoclonal antibodies to immunotherapies to new, personalized therapeutics...

Via Benzinga

The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗

June 07, 2021

Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.